BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Roslin Cells to Create Two Specialized Subsidiaries – Roslin Cell Therapies and Roslin Cell Sciences
Roslin Cells to Create Two Specialized Subsidiaries - Roslin Cell Therapies and Roslin Cell Sciences

Roslin Cells to Create Two Specialized Subsidiaries – Roslin Cell Therapies and Roslin Cell Sciences

January 27, 2016 By Cade Hildreth (CEO) Leave a Comment

Established in Edinburgh, UK, in 2006, Roslin Cells has spent the last decade developing into a leader in the “development, optimization, scale up and the GMP manufacture of Cell Therapy and Advanced Therapy Medicinal Products (ATMPs).” With major facilities in both Edinburgh and Cambridge, the company can produce large volumes of cell lines from different donors, allowing pharmaceutical researchers to assess how drug performance can differ from individual to individual.

Discover class-defining bioproduction tools.

On January 11th, 2016, Roslin Cells announced major news that it is creating two subsidiary companies, one to facilitate “process development and manufacture of cell therapies for clinical trials” and the other to “focus on the production and use of human induced Pluripotent Stem Cells (iPSCs) for drug discovery.” This will strengthen Roslin Cell’s position as a leader in both clinical-grade cell manufacturing and in iPSC production for drug discovery applications.

To learn more, view the full press release, published below with permission from Daria Olijnyk-Dallis, Business Development Executive for Roslin Cell Therapies.


Roslin Cells announces the creation of two commercially focused subsidiaries: Roslin Cell Therapies and Roslin Cell Sciences

PRESS RELEASE; Edinburgh, Scotland, 11th January 2016 — Roslin Cells Ltd., the Edinburgh and Cambridge based spin out from the world renowned Roslin Institute, announced today that it has established two subsidiary companies to accelerate the expansion of its commercial operations.  Roslin Cell Therapies will carry forward its process development and manufacture of cell therapies for clinical trials.  Roslin Cell Sciences will focus on the production and use of human induced Pluripotent Stem Cells (iPSCs) for drug discovery.

Rooster DevServices

Roslin Cell Therapies 

Roslin Cell Therapies builds on the wealth of expertise and industry recognition developed by Roslin Cells in the process development and manufacture of Cell Therapies and Advanced Therapy Medicinal Products (ATMPs).  Based at Edinburgh BioQuarter, where it operates purpose built clean room facilities, the company will continue to provide contract manufacturing services for clinical trial supply.

bitbio

Roslin Cell Sciences

Roslin Cell Sciences will focus on further development of Roslin Cells’ expertise in the creation of induced Pluripotent Stem Cells (iPSCs) for commercial and academic drug research. There is an increasing appreciation that iPSCs offer a wholly new means of evaluating new drugs and their suitability for particular patients. With facilities in both Edinburgh and Cambridge, UK, the company is capable of creating large numbers of iPS cell lines from cohorts of donors. Creating cell lines in this way will enable researchers to understand better how drug performance varies between individuals due to their genetic variation.

Pluristyx

Aidan Courtney, Chief Executive Officer stated “Since we founded the company in 2006, it has developed two distinct businesses both operating in rapidly developing markets – the manufacture of cell therapies and the use of iPSCs for research.  By creating two separate commercial entities, we will be best placed to maximise the growth and success of both.”

Press Contacts

iPSC-derived cardiomyocte therapy

Roslin Cell Therapies
Dr Daria Olijnyk-Dallis, Business Development Executive
Tel: +44 (0)131 658 5180; Mobile:  +44 (0)7867494071
Email: [email protected]; Web: www.roslincells.com/roslincelltherapies

Roslin Cell Sciences
Kevin Bruce, Head of Commercial
Tel: +44 (0)131 440 6543; Mobile: +44 (0)7825 393 287
Email: [email protected]; Web: www.roslincells.com/roslincellsciences


Want to be better informed than your competition? Get future stem cell industry updates.

 

About Us

BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.

Click here to view our global strategic reports for the stem cell and cord blood industry.

Rate this post

Filed Under: iPS Cells, MSCs, Stem Cells Tagged With: cell therapy, iPSC, market news, press release, Roslin Cells, stem cells

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

clean meat market

Clean Meat Market: Stem Cell Derived “Clean Meat” Attracts Billionaires

what are exosomes | definition

What are Exosomes, Exactly?

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.